【强生(JNJ.US)突破性疗法获优先审评资格 超80%患者肿瘤完全消失】智通财经APP获悉,今日,强生(JNJ.US)宣布,美国FDA已授予其创新膀胱内药物释放系统TAR-200新药申请(NDA)优先审评资格,用于治疗对卡介苗(BCG)无应答的高危非肌层浸润性膀胱癌(HR-NMIBC)伴原位瘤患者。根据新闻稿,TAR-200是旨在为膀胱癌治疗提供持续局部药物递送的首款膀胱内药物释放系统(iDRS)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.